Navidea biopharmaceuticals announces updated third-party asset valuation of tc99m tilmanocept for indications in rheumatoid arthritis for u.s. and eu markets

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the results of an updated third-party asset valuation of its rheumatoid arthritis (“ra”) diagnostic product candidate for both the u.s. and eu markets. the company engaged the independent third-party valuation firm, lifesci consulting (lifesci partners), to perform a u
NAVB Ratings Summary
NAVB Quant Ranking